1. A pharmaceutical composition comprising glycopyrronium chloride dissolved in an HFA propellant and, optionally, a co-solvent, characterized in that said composition contains an amount of 1M HCl in the range of 0.05-0.4 μg / μl. 2. The composition according to claim 1, where the range of the amount of 1M HCl is 0.19-0.25 μg / μl. The composition of claim 1, wherein the cosolvent is ethanol. 4. The composition according to claim 1, including glycopyrronium chloride in an amount in the range of 0.005-0.83% wt./wt. composition. 5. The composition according to claim 1, which further includes one or more pharmaceutically active ingredients selected from the group consisting of beta-2 agonists, corticosteroids, antimuscarinic agents and phosphodiesterase (IV) inhibitors. The composition according to claim 5, which further comprises formoterol fumarate. A composition according to claim 5 or 6, which further comprises beclomethasone dipropionate. A metered-dose inhaler containing a pharmaceutical composition according to any one of the preceding claims. A kit of parts comprising the pharmaceutical composition of claim 1 and further comprising one or more pharmaceutically active ingredients for separate, sequential or simultaneous administration, wherein said pharmaceutically active ingredients are selected from the group consisting of beta-2 agonists, corticosteroids, antimuscarinic agents, and phosphodiesterase (IV) inhibitors. 10. The use of the pharmaceutical composition according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment or prevention of respiratory diseases, such as COPD.11. The pharmaceutical composition according to claim 1 for use in the prevention or treatment of COPD. Aerosol filling method1. Фармацевтическая композиция, включающая гликопиррония хлорид, растворенный в пропелленте HFA, и, необязательно, сорастворитель, отличающаяся тем, что указанная композиция содержит количество 1M HCl в диапазоне 0,05-0,4 мкг/мкл.2. Компо
